TAR-200 not checked
Johnson & Johnson (Janssen) · JNJ-17000139
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Urinary Bladder Neoplasms (2 trials), Bladder Cancer, Non-Muscle Invasive Bladder Neoplasms
- Main trialPhase 3
- “The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.”In the company’s words, NCT04658862 on ClinicalTrials.gov
- Other names
- JNJ-17000139
Other drugs for Urinary Bladder Neoplasms
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- CetrelimabJohnson & Johnson (Janssen) · Phase 3
- Datopotamab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
Coming up3
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- 18 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
- 27 Nov 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Dec 2026 | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | |
| Phase 3Active, not recruiting | 18 Sep 2029 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) | |
| Phase 3Active, not recruiting | 27 Nov 2030 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | |
| Phase 2Active, not recruiting | 3 Jul 2025 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | |
| Phase 2Completed | 4 Feb 2025 | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder | |
| Phase 1Completed | 23 Dec 2019 | A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026